Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2667)	9/29/2001 9:23:09 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 4974

>> But is it for sale ? << Ponder, ponder, ponder........ Yes. But, I agree with your sentiment...... there's probably not much to stop Glass from letting the cash ride where it may. More power to Glass/Icahn if they pick something good outside of biotech. I still think that the potential royalty flow would add tons of "sexy" to a prospectus. Find some great functional genomics company and merge them with KDUS instead of doing a mezzanine? >> but in the current environment, it's understandable << Hey, I think that they did great. I was assuming that they'd do it at $4, before the run. Me <------- happy camper. >> Genomweb article on funding gives the new conventional wisdom << The IPO and secondary markets were buried deep by last week’s mass selling. We were looking at "dried up funding" pre-atrocity. BioCentury had done their "look for some down rounds" article about a month ago. I'm not certain that funding will be that tight. The sector is very, very strong. We'll see. I personally believe that the sector is so strong and that small caps are so outrageously undervalued that a sector rally will attract lots of interest. A group of SI biofreaks participated in a round that closed last week. Great opportunity.